{"data":{"id":"us-ak/as-08.64.367","jurisdiction":"us-ak","citation":"AS 08.64.367","heading":"Use of amygdalin (laetrile); investigational drugs, biological products, or devices.","body":"(a) A physician may not be subject to disciplinary action by the board for prescribing or administering amygdalin (laetrile) to a patient under the physician's care who has requested the substance unless the board in a hearing conducted under AS 44.62 (Administrative Procedure Act) has made a formal finding that the substance is harmful.\n(b) A hospital or health facility may not interfere with the physician-patient relationship by restricting or forbidding the use of amygdalin (laetrile) when prescribed or administered by a physician and requested by a patient unless the substance as prescribed or administered by the physician is found to be harmful by the board in a hearing conducted under the provisions of AS 44.62 (Administrative Procedure Act).\n(c) A physician may not be subject to disciplinary action by the board for prescribing, dispensing, or administering an investigational drug, biological product, or device, or providing related treatment, to a patient for the purpose of sustaining the patient's life if the patient\n(1) has a terminal illness;\n(2) is ineligible or unable to participate in a current clinical trial for the investigational drug, biological product, or device;\n(3) has considered, after consultation with the physician, all other treatment options currently approved by the United States Food and Drug Administration; and\n(4) has given informed consent in writing for the use of the investigational drug, biological product, or device.\n(d) In this section,\n(1) “investigational drug, biological product, or device” means a drug, biological product, or device that has successfully completed Phase 1 studies of clinical trials for investigation and remains in ongoing clinical trials under Phase 2 or Phase 3 or is in the new drug application process following Phase 3 of clinical trials, but has not been approved for general use by the United States Food and Drug Administration;\n(2) “terminal illness” means a disease that, without life-sustaining procedures, will result in death in the near future or a state of permanent unconsciousness from which recovery is unlikely.","path":["Title 8. Business and Professions.","Chapter 64. Medicine.","Article 3. Miscellaneous Provisions."],"source_url":"https://www.akleg.gov/basis/statutes.asp#08.64.367","current_through":"Alaska Statutes 2025 (34th Legislature, 2025-2026)","vintage":"","retrieved_at":"2026-09-02T06:16:30Z","sha256":"e8e68ea09f15484b4bd749015a8742bcad7ffa1820370034a140eb4efa378887","source_id":"us-ak","stale":false,"prev":"us-ak/as-08.64.366","next":"us-ak/as-08.64.368"},"notice":"GroundRules: Original legal text. Not legal advice."}